rs2229616 — MC4R V103I

Missense variant in MC4R converting valine to isoleucine at position 103; the I103 allele confers modest but replicable protection against obesity and improves metabolic syndrome components

See your personal result for MC4R

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

MC4R V103I — A Rare Protective Variant in the Appetite Control System

The melanocortin-4 receptor (MC4R) is the master satiety switch in your hypothalamus. When activated by alpha-melanocyte stimulating hormone (α-MSH) — itself triggered by leptin signaling from fat tissue — MC4R fires a stop-eating signal and ramps up energy expenditure. Most MC4R mutations impair this system, causing severe early-onset obesity. The V103I variant (rs2229616) is unusual: it works in the opposite direction. Carriers of the I103 allele11 I103 allele
the isoleucine-103 form of MC4R, present in roughly 4% of people of European descent show reproducible protection against obesity and improved metabolic profiles across multiple large independent cohorts.

The Mechanism

MC4R is a G protein-coupled receptor22 G protein-coupled receptor
a seven-transmembrane protein that converts extracellular hormone signals into intracellular responses embedded in hypothalamic neurons. At amino acid position 103, valine (the common allele) sits in the second transmembrane domain of the receptor. The V103I substitution replaces valine with isoleucine — both are hydrophobic, branched-chain amino acids, and the change is biochemically conservative.

In vitro functional studies show that the Ile103 receptor is not straightforwardly more active than the Val103 form in standard assays; the two receptors have comparable binding affinity and cAMP signaling in transfected cell lines. The most credible mechanistic hypothesis is that Ile103 alters receptor trafficking, membrane stability, or basal constitutive activity in ways that are relevant in intact hypothalamic circuits but difficult to detect in simplified cell models. Functional studies to date33 Functional studies to date
reviewed in Brönner et al. 2006 and Stutzmann et al. 2007 have not identified a clear gain-of-function mechanism, leaving this as an open question — but the epidemiological protection signal is robust enough to treat as established.

The Evidence

The protective association is one of the most consistently replicated rare-variant findings in obesity genetics. A 2004 meta-analysis44 2004 meta-analysis
combining transmission disequilibrium data from 520 trios with two case-control studies and 12 published studies across 7,713 individuals found that I103 carriers had a 31% lower odds of obesity (OR=0.69, 95% CI 0.50–0.96, p=0.03). The effect was predominantly observed in European-origin samples.

A larger 2007 meta-analysis55 2007 meta-analysis
nine independent European cohorts, n=16,797 confirmed the protection (OR=0.80, p=0.002), showing the variant accounts for approximately 2% of population-level obesity prevention — meaningful for a variant present in only 4% of individuals. The same study found V103I and the rarer I251L variant together tag the "protective face" of MC4R: while most MC4R mutations cause obesity, these two variants appear to provide slightly enhanced MC4R tone.

A 2005 population survey66 2005 population survey
two cohorts totaling 7,937 German adults quantified the BMI effect: CT heterozygotes showed a mean decrease of 0.52 BMI units (95% CI −0.02 to −1.03, p=0.043) and an odds ratio of 0.75 for above-median BMI (95% CI 0.59–0.95, p=0.017). Effects were consistent across both sexes.

Beyond weight, the KORA study77 KORA study
7,888 adults from two population-based German surveys showed that I103 carriers had markedly lower metabolic syndrome risk (OR=0.46 for having three or more metabolic syndrome components, p=0.003), alongside reduced waist circumference (−1.46 cm, p=0.020), lower HbA1c (−0.09%, p=0.040), and a trend toward higher HDL cholesterol (+1.76 mg/dl, p=0.056).

A separate cardiovascular study88 separate cardiovascular study
1,173 consecutive cardiac catheterization patients found I103 heterozygotes had substantially lower serum triglycerides (127 vs 168 mg/dl, p=0.001), an effect surviving Bonferroni correction. No homozygous I103 carriers were identified, consistent with the variant's rarity.

The homozygous TT genotype (two I103 alleles) is extremely rare — estimated at less than 0.04% globally — and no large study has assembled enough TT individuals to characterize them independently. Most published findings are based on CT heterozygotes.

Practical Implications

For CT carriers, the protective signal translates to modestly better metabolic starting conditions: lower average BMI, better triglyceride profiles, reduced metabolic syndrome risk. This does not confer immunity to obesity — the effect size (~0.5 BMI units) is small relative to environmental influences — but it does mean your MC4R satiety circuitry may be slightly more responsive than average.

The practical corollary is that monitoring strategies that benefit MC4R common-allele carriers (e.g., aggressive metabolic syndrome screening) may be less urgent for I103 carriers. However, because the TT genotype is so rare and under-characterized, and because other MC4R variants (rs17782313, rs12970134) can simultaneously increase risk, individual genetic context matters more than a single protective variant.

Interactions

rs17782313 (MC4R downstream regulatory variant): This is the major common MC4R obesity GWAS hit, which increases obesity risk by reducing MC4R promoter expression. Carriers of the rs17782313 C (risk) allele have blunted MC4R signaling, while V103I I103 carriers have a slight enhancement. These two MC4R variants can co-occur and their effects are likely partially antagonistic — though no study has formally examined the combined genotype at sufficient sample size. If you carry both, consider the rs17782313 risk signal dominant given its larger population-level effect.

rs12970134 and rs571312: Additional MC4R-region variants in linkage disequilibrium with rs17782313. These tag the same regulatory haplotype and their risk contributions overlap rather than add.

Genotype Interpretations

What each possible genotype means for this variant.

CC Common MC4R Normal

Standard MC4R valine-103 — typical appetite regulation

You carry two copies of the common valine-103 allele of MC4R, shared by approximately 96% of people of European descent. This is the population-standard MC4R configuration — your satiety receptor functions in the typical range, without the modest protective effect seen in I103 carriers. No increased obesity risk attributable to this specific variant; other MC4R variants and broader lifestyle factors determine your individual metabolic trajectory.

CT I103 Carrier Beneficial

One copy of the protective I103 allele — modest metabolic advantage

The V103I substitution replaces valine with isoleucine in the second transmembrane domain of MC4R. Both are hydrophobic, branched-chain amino acids, making this a conservative missense change. Standard in vitro assays show comparable binding affinity and cAMP signaling between Val103 and Ile103 receptors, yet the population-level protective signal is robust across multiple independent studies totaling tens of thousands of individuals. The most likely explanation involves subtle effects on receptor trafficking, membrane stability, or constitutive (ligand-independent) activity that only manifest in intact hypothalamic circuits under physiological conditions.

Because CT heterozygotes are rare (~4%) and TT homozygotes extremely rare (<0.04%), virtually all published findings on this variant reflect heterozygous CT individuals. The codominant interpretation — where TT would be expected to show stronger protection than CT — is plausible but unverified due to insufficient TT sample sizes.

TT Homozygous I103 Beneficial

Two copies of the protective I103 allele — rare genotype, modest metabolic advantage

The I103 allele frequency is approximately 1.9% in Europeans and 1.5–1.9% in other populations. At Hardy-Weinberg equilibrium, TT homozygosity should appear in roughly 0.036% of European individuals — approximately 1 in 2,800 people. In a study of 7,937 German adults, no TT homozygotes were identified, consistent with this rarity. All published protective associations (OR=0.69–0.80 across meta-analyses) are derived almost entirely from CT heterozygotes.

The biochemical rationale for enhanced protection in TT is plausible — two Ile103 alleles would presumably double whatever subtle functional enhancement each copy provides — but the effect size in CT is modest enough that a doubling would still represent only a minor phenotypic difference. In practice, TT individuals should monitor the same metabolic biomarkers as CT carriers and not assume complete metabolic protection.